Injection Device

• US 20160129195A1
• Filed: 06/11/2014
• Published: 05/12/2016
• Est. Priority Date: 06/11/2013
• Status: Active Grant

• Current Assignee: Cilag Gmbh International (Johnson & Johnson)
• Original Assignee: Cilag Gmbh International (Johnson & Johnson)
• Inventors: Bitar, Ahmad, Jennings, Douglas Ivan
• Granted Patent: US 11,123,492 B2
• Time in Patent Office: Days
• US Class Current: 1/1
• CPC Class Codes: A61M 2005/2006 Having specific accessories
• CPC Class Codes: A61M 2005/206 With automatic needle insertion
• CPC Class Codes: A61M 2005/208 Release is possible only when device is pushed against the skin, e.g. using a trigger which is blocked or inactive when the device is not pushed against the skin
• CPC Class Codes: A61M 2005/2403 Ampoule inserted into the ampoule holder
• CPC Class Codes: A61M 2005/3125 specific display means, e.g. to indicate dose setting
• CPC Class Codes: A61M 2005/3247 Means to impede repositioning of protection sleeve from needle covering to needle uncovering position
• CPC Class Codes: A61M 2005/3267 Biased sleeves where the needle is uncovered by insertion of the needle into a patient's body
• CPC Class Codes: A61M 5/2033 Spring-loaded one-shot injectors with or without automatic needle insertion multishot dosing syringes A61M5/31525, needle insertion only A61M5/3287
• CPC Class Codes: A61M 5/31501 Means for blocking or restricting the movement of the rod or piston A61M5/5013 takes precedence
• CPC Class Codes: A61M 5/31586 performed by rotationally moving or pivoted actuator, e.g. an injection lever or handle
• CPC Class Codes: A61M 5/3204 Needle cap remover, i.e. devices to dislodge protection cover from needle or needle hub, e.g. deshielding devices

Abstract

An injection device comprises an actuator adapted when actuated to cause commencement of an injection sequence; a locking mechanism adapted to be moved between a locked position in which the locking mechanism prevents the actuator from being actuated, and an unlocked position in which the actuator can be actuated to cause commencement of the injection sequence. An indicator is configured to provide a visual indication of whether the locking mechanism is in its locked position or in its unlocked position.

Claims

1. An injection device comprising:

an actuator adapted when actuated to cause commencement of an injection sequence;

a locking mechanism adapted to be moved between a locked position in which the locking mechanism prevents the actuator from being actuated, and an unlocked position in which the actuator can be actuated to cause commencement of the injection sequence; and

an indicator configured to provide a visual indication of whether the locking mechanism is in its locked position or in its unlocked position.

2. The injection device of claim 1, wherein the indicator comprises an indicator component on the indicator which moves with the locking mechanism as it moves between its locked and unlocked positions.

3. The injection device of claim 2, further comprising a housing to which the actuator and locking mechanism are moveably mounted.

4. The injection device of claim 3, wherein the housing comprises an indicator aperture.

5. The injection device of claim 4, wherein at least part or all of the indicator component is visible through the indicator aperture when the locking mechanism is in its locked position.

6. The injection device of claim 5, wherein the indicator aperture is wholly covered by at least a part of the indicator component when the locking mechanism is in its locked position, and at least part of the indicator aperture is not covered by the indicator component when the locking mechanism is not in its locked position.

7. The injection device of claim 4, wherein at least part or all of the indicator component is visible through the indicator aperture when the locking mechanism is in its unlocked position.

8. The injection device of claim 5, wherein the indicator aperture is wholly covered by at least a part of the indicator component when the locking mechanism is in its unlocked position, and at least part of the indicator aperture is not covered by the indicator component when the locking mechanism is not in its unlocked position.

9. The injection device of any one of the preceding claims, wherein the contact portion is adapted to contact an engagement surface of the actuator when the locking mechanism is in it locked position.

10. The injection device of any one of the preceding claims, wherein the contact portion is adapted not to contact an engagement surface of the actuator when the locking mechanism is in its unlocked position.

11. The injection device of claim 9 or claim 10, wherein the locking mechanism is moveable between its locked position and its unlocked position such that the contact portion moves from a position in which it contacts the engagement surface of the actuator to a position in which it no longer contacts the engagement surface of the actuator.

15. The injection device of any one of the preceding claims, wherein the locking mechanism comprises a sliding component which slides to move the locking mechanism between its locked and unlocked positions.

16. The injection device of claim 15, wherein the sliding component is configured to slide inwardly into the injection device to move it from its locked position to its unlocked position.

17. The injection device of claim 16, wherein the sliding component projects from a sliding component opening in the housing when it is in its unlocked position.

19. The injection device of any one of claims 15 to 18, wherein the sliding component is a sliding sleeve.

20. The injection device of any one of the preceding claims, wherein the actuator rotates between its first and second positions about a pivot.

22. An injection device according to any of the preceding claims

containing a substance selected from the group consisting of:

golimumab, hormones, antitoxins, substances for the control of pain, substances for the control of thrombosis, substances for the control or elimination of infection, peptides, proteins, human insulin or a human insulin analogue or derivative, polysaccharide, DNA, RNA, enzymes, antibodies, oligonucleotide, antiallergics, antihistamines, anti-inflammatories, corticosteroids, disease modifying anti-rheumatic drugs, erythropoietin, or vaccines,

for use in the treatment or prevention of rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, ulcerative colitis, hormone deficiency, toxicity, pain, thrombosis, infection, diabetes mellitus, diabetic retinopathy, acute coronary syndrome, angina, myocardial infarction, atherosclerosis, cancer, macular degeneration, allergy, hay fever, inflammation, anaemia, or myelodysplasia, or in the expression of protective immunity.

23. A substance selected from the group consisting of:

golimumab, hormones, antitoxins, substances for the control of pain, substances for the control of thrombosis, substances for the control or elimination of infection, peptides, proteins, human insulin or a human insulin analogue or derivative, polysaccharide, DNA, RNA, enzymes, antibodies, oligonucleotide, antiallergics, antihistamines, anti-inflammatories, corticosteroids, disease modifying anti-rheumatic drugs, erythropoietin, or vaccines,

for use in the treatment or prevention of rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, ulcerative colitis, hormone deficiency, toxicity, pain, thrombosis, infection, diabetes mellitus, diabetic retinopathy, acute coronary syndrome, angina, myocardial infarction, atherosclerosis, cancer, macular degeneration, allergy, hay fever, inflammation, anaemia, or myelodysplasia, or in the expression of protective immunity,

by delivery of said substance to a human subject using an injection device according to any one of claims 1 to 21.

24. An injection device for use in the treatment or prevention rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, ulcerative colitis, hormone deficiency, toxicity, pain, thrombosis, infection, diabetes mellitus, diabetic retinopathy, acute coronary syndrome, angina, myocardial infarction, atherosclerosis, cancer, macular degeneration, allergy, hay fever, inflammation, anaemia, or myelodysplasia, or in the expression of protective immunity,

by delivery of a substance selected from the group consisting of:

golimumab, hormones, antitoxins, substances for the control of pain, substances for the control of thrombosis, substances for the control or elimination of infection, peptides, proteins, human insulin or a human insulin analogue or derivative, polysaccharide, DNA, RNA, enzymes, antibodies, oligonucleotide, antiallergics, antihistamines, anti-inflammatories, corticosteroids, disease modifying anti-rheumatic drugs, erythropoietin, or vaccines,

to a human subject by using the injection device, wherein the injection device is an injection device according to any one of claims 1 to 21.

12. The injection device wherein the actuator moves between a first position in which commencement of the injection sequence is prevented, and a second position in which commencement of the injection sequence occurs.

13. The injection device of claim 12, further comprising a drive mechanism, wherein the actuator comprises a locking surface which inhibits the drive mechanism when the actuator is in its first position and which does not inhibit the drive mechanism when the drive mechanism is in its second position.

14. The injection device of claim 13, further comprising a syringe which is moveable by the drive mechanism on commencement of the injection sequence from a position in which the syringe is wholly contained within a body of the injection device to a position in which a needle of the syringe extends from a housing of the injection device via an injection opening, wherein the drive mechanism is adapted to expel contents of the syringe via the needle when the syringe is in its extended position.

18. The injection device of claim 17, when dependant on claim 14, wherein the sliding component opening is the injection opening.

21. An injection device substantially as described herein with reference to and as shown in the accompanying drawings.